Study of D-2570 in Subjects With Non-Segmental Vitiligo

This study tests D-2570, an investigational drug, in people with non-segmental vitiligo to check its safety and effect on skin discoloration. Eligible participants will take D-2570, or a placebo, once daily for 24 weeks in a double-blind setting. Most will then continue into a 24-week extension phase All participants will have a 4-week safety follow-up after treatment ends, with regular check-ups and blood tests throughout the study.

NCT Number	NCT07625891
Lead Sponsor	InventisBio Co., Ltd
Conditions	Vitiligo, Non-Segmental Vitiligo (NSV)
Enrollment	160 participants
Start Date	2026-06-11
Primary Completion	2027-11 (estimated)
Study Completion	2028-05 (estimated)
Updated on ClinicalTrials.gov	2026-07-15